Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
We now propose to investigate the combination of CHOP-Rituxan plus PEG-Filgrastim
(PEG-filgrastim) and GM-CSF. PEG-Filgrastim would be given in order to allow us to administer
the chemotherapy courses every 2 weeks with the practical advantage of requiring only one
dose of PEG-filgrastim instead of daily doses of G-CSF.